SRR8518423
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- ANGIOGENESIS+0.520
- CHOLESTEROL_HOMEOSTASIS+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- INTERFERON_GAMMA_RESPONSE+0.440
- APICAL_SURFACE+0.410
- COAGULATION+0.410
- HYPOXIA+0.410
- INTERFERON_ALPHA_RESPONSE+0.410
- MTORC1_SIGNALING+0.390
Top 10 suppressed
- E2F_TARGETS-0.330
- G2M_CHECKPOINT-0.320
- DNA_REPAIR-0.310
- MITOTIC_SPINDLE-0.180
- SPERMATOGENESIS-0.150
- KRAS_SIGNALING_DN-0.040
- PI3K_AKT_MTOR_SIGNALING+0.010
- PANCREAS_BETA_CELLS+0.020
- BILE_ACID_METABOLISM+0.040
- MYC_TARGETS_V1+0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_N1E0H8YQ | low-grade glioma | — | 0.917 |
| 2 | SRR26320076 | — | — | 0.915 |
| 3 | BS_77CDMEY4 | Ganglioglioma | — | 0.910 |
| 4 | EPT0508 | EPN | Posterior Fossa EPN | 0.902 |
| 5 | SRR3147740 | — | — | 0.896 |
| 6 | SRR1323196 | GTEX | — | 0.895 |
| 7 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.895 |
| 8 | BS_2YCJV2VV | low-grade glioma | — | 0.890 |
| 9 | SRR1347688 | GTEX | — | 0.889 |
| 10 | BS_C51RB0YR | low-grade glioma | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.470 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| HYPOXIA | 0.410 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |